Enoxaparin sodium

also known as enoxaparin · Lovenox · Clexane · enoxaparine · RP54563 · XRP4563 · Klexane · Sodium enoxaparin · +18 more

Other / unclassified targets SERPINC1 via activation

Developed for: venous thromboembolism · COVID-19 · pulmonary embolism · thrombotic disease · blood coagulation disease · myocardial infarction · acute coronary syndrome · coronary artery disorder
+65 more
· fetal growth restriction · pneumonia · preeclampsia · cancer · cirrhosis of liver · infertility disorder · intermediate coronary syndrome · malignant pancreatic neoplasm · pregnancy disorder · ST-elevation myocardial infarction · acute myocardial infarction · ischemic stroke · non-small cell lung carcinoma · obesity disorder · osteoarthritis, hip · placental insufficiency · small cell lung carcinoma · thrombophilia · viral pneumonia · acute respiratory distress syndrome · atrial fibrillation · basilar artery occlusion · brain injury · cardiac valvular defect · cardiovascular disorder · chronic liver failure · COVID-19–associated multisystem inflammatory syndrome in adults · end stage renal failure · esophageal cancer · female infertility · gastric cancer · gastroesophageal cancer · habitual spontaneous abortion · heart failure · hemorrhagic stroke · intracranial embolism · kidney disorder · myocardial ischemia · nephrotic syndrome · pancreatic adenocarcinoma · placental abruption · portal vein thrombosis · pregnancy disorder with abortive outcome · pregnancy loss, recurrent, 4 · protein S deficiency · psoriasis · radiation-induced disorder · spinal cord injury · strictly posterior acute myocardial infarction · vein disorder · vulvodynia · acute respiratory failure · antiphospholipid syndrome · arterial occlusion · carotid artery dissection · chronic obstructive pulmonary disease · digestive system neoplasm · disease of bone structure · heart disorder · intracerebral hemorrhage · isolated splenic vein thrombosis · osteoarthritis, knee · staphylococcus aureus infection · thrombophlebitis · vertebral artery dissection
Investigated by: Sanofi · University of Utah · Assistance Publique - Hôpitaux de Paris · Boehringer Ingelheim · Massachusetts General Hospital · Azidus Brasil
+285 more
· Johns Hopkins All Children's Hospital · University Hospital, Geneva · University of Iowa · Weill Medical College of Cornell University · Aventis Pharmaceuticals · Beijing Anzhen Hospital · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Bristol-Myers Squibb · CONKO-Studiengruppe · Canadian Institutes of Health Research (CIHR) · Chemi S.p.A. · Children's Hospital of Philadelphia · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Hamilton Health Sciences Corporation · Helsinki University Central Hospital · Les Laboratoires des Médicaments Stériles · Maria Fareri Children's Hospital · McMaster University · Medical University of Vienna · New York Presbyterian Hospital · North Shore Medical Center · Peking Union Medical College Hospital · Sheffield Teaching Hospitals NHS Foundation Trust · The Cleveland Clinic · Thrombosis Research Institute · Unity Health Toronto · University Hospital of Saint-Etienne · University Hospital, Brest · University of Manitoba · University of Sao Paulo · University of Sao Paulo General Hospital · University of Texas Southwestern Medical Center · University of Vermont Medical Center · Yale University · ASST Fatebenefratelli Sacco · Academy of Finland · Ahmed Elgazzar Hospital · Ain Shams University · Al Ain Hospital · Alberta Health services · Alexandre Tran · Amgen · Aotearoa Clinical Trials · AstraZeneca · Auckland City Hospital · Aurora Clinical Research · Australasian Society for Infectious Diseases · Australian and New Zealand Intensive Care Research Centre · Avanti PC · BJC HealthCare · Barnes-Jewish Hospital · Bayer · Beijing Chuiyangliu Hospital · Beijing Friendship Hospital · Beijing Hospital · Beijing Obstetrics and Gynecology Hospital · Beneficência Portuguesa de São Paulo · Blau Farmaceutica S.A. · Brazilian Clinical Research Institute · Brazilian Research In Intensive Care Network · CH du Puy en Velay, Hôpital Emile Roux · CHU Hôpital Maison Blanche, 45 Rue Cognacq-Jay 51092 REIMS Cedex · CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang · Cairo University · Calydial · Canadian Critical Care Trials Group · Canadian Heart Research Centre · Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network · Cardiff University · Centre Hospitalier Universitaire Vaudois · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Centre de dialyse d'Alès · Centre hospitalier de Chambéry · all 291 on the full record

Regulatory milestones approvals, filings & regulatory actions · 10 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Thorinane	—	2016-09-14	europa.eu ↗
Label expansions (8)	US (FDA)	LOVENOX (PRESERVATIVE FREE)	—	1995-03-09 – 2000-11-17	fda.gov ↗
Approved	US (FDA)	LOVENOX (PRESERVATIVE FREE)	—	1993-03-29	fda.gov ↗

Trials 173 · started per year

today

US approved 1993

EU approved 2016

1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02704052	Mar 2016 → Jul 2018	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 112 trials
Phase 1	NCT07312851	Jan → Jun 2026	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06517563	Aug → Dec 2024	blood coagulation disease	VarmX B.V.	Completed	No outcome recorded
Phase 1	NCT04976465	Jan 2018 → Jul 2025 overdue	pregnancy disorder, systemic lupus erythematosus	Qilu Hospital of Shandong University	Recruiting	No outcome recorded
Phase 1	NCT03363477	Sep → Dec 2015	—	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 1	NCT02325479	Jan → May 2015	infertility disorder	The Egyptian IVF-ET Center	Completed	No outcome recorded
Phase 1	NCT02232802	Aug → Dec 2014	—	Chemi S.p.A.	Completed	No outcome recorded
Phase 1	NCT02081950	Mar 2014	—	Chemi S.p.A.	Completed	No outcome recorded
Phase 1	NCT02152423	Jun 2013 → Jan 2014	acute coronary syndrome	University of Monastir	Completed	No outcome recorded
Phase 1	NCT01692158	Mar → Nov 2013	—	Azidus Brasil	Completed	No outcome recorded
Phase 1	NCT01692171	Feb → Oct 2013	—	Azidus Brasil	Completed	No outcome recorded
Phase 1	NCT01014403	Nov 2009 → May 2011	traumatic brain injury, venous thromboembolism	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 1	NCT02171559	Aug → Sep 2008	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT04402762	Dec 2019 → Apr 2020	—	Indonesia University	Completed	No outcome recorded
Phase 1/2	NCT01945879	Jan 2003 → Apr 2004	malignant pancreatic neoplasm	CONKO-Studiengruppe	Completed	No outcome recorded
Phase 228 trials
Phase 2	NCT07499037	Jan 2027 → Sep 2029 expected	heart failure, pneumonia	University Hospital Ostrava	Not yet recruiting	No outcome recorded
Phase 2	NCT06531525	Aug 2024 → Dec 2026 expected	pregnancy disorder, protein S deficiency	Peking University People's Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05895136	Jul 2024 → Sep 2025 overdue	chronic liver failure, cirrhosis of liver	European Foundation for Study of Chronic Liver Failure	Recruiting	No outcome recorded
Phase 2	NCT06004674	Dec 2023 → Mar 2026 overdue	—	Endeavor Health	Recruiting	No outcome recorded
Phase 2	NCT06118957	Oct 2023 → Jul 2024	venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT04354155	Jun 2020 → Jun 2021	COVID-19, venous thromboembolism	Johns Hopkins All Children's Hospital	Completed	No outcome recorded
Phase 2	NCT04377997	May 2020 → Jun 2022	COVID-19, cardiovascular disorder	Massachusetts General Hospital	Unknown	No outcome recorded
Phase 2	NCT03812328	Feb → Oct 2019	venous thromboembolism	Tetherex Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 2	NCT03339349	Nov 2017 → Jun 2019	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT03251963	Sep 2017 → Mar 2019	venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT03200613	Sep 2017 → Jul 2019	spinal cord injury, venous thromboembolism	McMaster University	Terminated	No outcome recorded
Phase 2	NCT03212365	Jul 2017 → Jun 2019	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT03003390	Apr 2017 → Aug 2019	venous thromboembolism	Yale University	Terminated	No outcome recorded
Phase 2	NCT03254511	Jul 2016 → Dec 2017	esophageal cancer	Mashhad University of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT02411292	Mar 2015 → Mar 2016	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 2	NCT02159287	Jan 2014 → Feb 2016	intracranial embolism	Shiraz University of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT01817257	Dec 2013 → Feb 2015	cancer, pulmonary embolism, thrombotic disease, venous thromboembolism	Cardiff University	Terminated	No outcome recorded
Phase 2	NCT01149304	Jun 2009 → Nov 2017	metastasis from malignant tumor of colon, radiation-induced disorder	University of Magdeburg	Completed	No outcome recorded
Phase 2	NCT00908960	May 2009 → Apr 2012	cancer	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 2	NCT00874484	Mar 2009 → Apr 2011	vulvodynia	Western Galilee Hospital-Nahariya	Completed	No outcome recorded
Phase 2	NCT00916669	Jul 2008 → Jul 2010	small cell lung carcinoma	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 2	NCT00633061	Jun 2008 → Jun 2011	childhood malignant neoplasm, prosthesis-related infectious disease, vascular occlusion disorder, venous thromboembolism	University of Texas Southwestern Medical Center	Terminated	No outcome recorded
Phase 2	NCT00426127	Nov 2006 → Jan 2009	malignant pancreatic neoplasm	University of Iowa	Terminated	No outcome recorded
Phase 2	NCT01051778	Jun 2006 → Nov 2009	habitual spontaneous abortion	Cairo University	Completed	No outcome recorded
Phase 2	NCT00331838	May 2006 → Jun 2007	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 2	NCT00375609	May 2006 → Jan 2007	venous thromboembolism	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00306254	Mar 2006 → Jul 2007	venous thromboembolism	Pfizer	Completed	No outcome recorded
Phase 2	NCT00402467	Feb → Nov 2004	venous thromboembolism	Bayer	Completed	No outcome recorded

Phase 2/38 trials
Phase 2/3	NCT06662253	Jan 2025 → Jun 2026 overdue	venous thromboembolism	Alexandre Tran	Not yet recruiting	No outcome recorded
Phase 2/3	NCT04924322	May 2022 → Apr 2027 expected	vein disorder	Yale University	Recruiting	No outcome recorded
Phase 2/3	NCT04990830	Feb → Apr 2021	acute respiratory distress syndrome	Istanbul University	Completed	No outcome recorded
Phase 2/3	NCT04372589	May 2020 → May 2021	COVID-19, pneumonia	University of Manitoba	Completed	No outcome recorded
Phase 2/3	NCT04558892	Oct 2015 → Nov 2018	nephrotic syndrome	Military Institute od Medicine National Research Institute	Terminated	No outcome recorded
Phase 2/3	NCT01590173	Jan 2012 → Jul 2016	infertility disorder	National and Kapodistrian University of Athens	Completed	No outcome recorded
Phase 2/3	NCT00785421	Apr 2004 → Jan 2009	pancreatic adenocarcinoma	CONKO-Studiengruppe	Completed	No outcome recorded
Phase 2/3	NCT00077844	Jan 2004 → Sep 2005	—	Sanofi	Completed	No outcome recorded
Phase 353 trials
Phase 3	NCT06628778	Apr 2027 → Apr 2034 expected	venous thromboembolism	Johns Hopkins All Children's Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT07140211	Oct 2025 → Aug 2030 expected	puerperal disorder, venous thromboembolism	Marc Blondon	Recruiting	No outcome recorded
Phase 3	NCT06494878	Apr 2025 → Aug 2030 expected	venous thromboembolism	University of Calgary	Not yet recruiting	No outcome recorded
Phase 3	NCT06153394	Jun 2024 → Feb 2025 overdue	liver disorder, thrombophilia, thrombotic disease	Western University, Canada	Not yet recruiting	No outcome recorded
Phase 3	NCT05848713	Oct 2023 → Mar 2028 expected	pneumonia	University of Manitoba	Recruiting	No outcome recorded
Phase 3	NCT04762992	Jul 2022 → Jul 2026 overdue	fetal growth restriction, preeclampsia	Centro Hospitalar de Lisboa Central	Enrolling by invitation	No outcome recorded
Phase 3	NCT05878899	May 2022 → Mar 2023	venous thromboembolism	University Hospital, Geneva	Completed	No outcome recorded
Phase 3	NCT04528888	Nov 2020 → Jun 2021	COVID-19, blood coagulation disease, viral pneumonia	Massimo Girardis	Unknown	No outcome recorded
Phase 3	NCT04600141	Nov 2020 → Oct 2021	COVID-19	University of Sao Paulo	Completed	No outcome recorded
Phase 3	NCT04492254	Oct 2020 → Nov 2021	COVID-19	Thrombosis Research Institute	Terminated	No outcome recorded
Phase 3	NCT04486508	Jul 2020 → Apr 2021	COVID-19	Rajaie Cardiovascular Medical and Research Center	Completed	No outcome recorded
Phase 3	NCT04483960	Jul 2020 → Jul 2025	COVID-19	University of Melbourne	Unknown	No outcome recorded
Phase 3	NCT04646655	Jul 2020 → Oct 2022	COVID-19, thrombotic disease	ASST Fatebenefratelli Sacco	Completed	No outcome recorded
Phase 3	NCT04485429	Jul 2020 → Dec 2022	COVID-19	D'Or Institute for Research and Education	Withdrawn	No outcome recorded
Phase 3	NCT04444700	Jul 2020 → May 2021	COVID-19, blood coagulation disease, severe acute respiratory syndrome, venous thromboembolism	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 3	NCT04400799	Jun 2020 → Feb 2022	COVID-19, venous thromboembolism	University of Zurich	Terminated	No outcome recorded
Phase 3	NCT04408235	Jun 2020 → Jun 2021	COVID-19, blood coagulation disease, viral pneumonia	University Hospital of Modena	Unknown	No outcome recorded
Phase 3	NCT04362085	May 2020 → May 2021	COVID-19	Unity Health Toronto	Completed	No outcome recorded
Phase 3	NCT04345848	Apr 2020 → Jun 2021	COVID-19	University Hospital, Geneva	Terminated	No outcome recorded
Phase 3	NCT04401293	Apr 2020 → May 2021	COVID-19	Northwell Health	Completed	No outcome recorded
Phase 3	NCT03083184	Feb 2018 → Dec 2026 expected	—	University Hospital, Clermont-Ferrand	Recruiting	No outcome recorded
Phase 3	NCT02984384	Apr 2017 → Feb 2022	thrombotic disease	Major Extremity Trauma Research Consortium	Completed	No outcome recorded
Phase 3	NCT02798471	Mar 2017 → May 2022	pulmonary embolism, venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT02672566	Jul 2016 → Sep 2019	fetal growth restriction	University Hospital of Saint-Etienne	Completed	No outcome recorded
Phase 3	NCT02486666	Mar 2016 → Dec 2022	venous thromboembolism	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 3	NCT02271295	Jul 2015 → Jul 2019	cirrhosis of liver	Assistance Publique - Hôpitaux de Paris	Suspended	No outcome recorded
Phase 3	NCT01308528	Feb 2015 → Feb 2017	venous thromboembolism	Cristália Produtos Químicos Farmacêuticos Ltda.	Completed	No outcome recorded
Phase 3	NCT01707732	Nov 2012 → Apr 2015	—	University Hospital, Rouen	Completed	No outcome recorded
Phase 3	NCT01356992	Jul 2012 → Jul 2013	intermediate coronary syndrome, myocardial infarction	Eurofarma Laboratorios S.A.	Terminated	No outcome recorded
Phase 3	NCT01573169	May 2012 → Mar 2020	hemorrhagic stroke, venous thromboembolism	University Of Perugia	Terminated	No outcome recorded
Phase 3	NCT01388322	Mar 2012 → Jun 2016	placental insufficiency, preeclampsia	Hospital Universitari Vall d'Hebron Research Institute	Completed	No outcome recorded
Phase 3	NCT01448746	Oct 2011 → Jan 2016	venous thromboembolism	The Catholic University of Korea	Unknown	No outcome recorded
Phase 3	NCT01474902	Aug 2011 → Aug 2015	venous thromboembolism	The Hospital for Sick Children	Withdrawn	No outcome recorded
Phase 3	NCT01058759	Nov 2009 → Feb 2011	non-small cell lung carcinoma	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT01356329	Oct 2009 → Aug 2016	female reproductive system neoplasm	National Guard Health Affairs	Suspended	No outcome recorded
Phase 3	NCT00986765	Jun 2009 → Nov 2015	preeclampsia	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00882635	Oct 2008 → Jun 2012	acute myocardial infarction	Robert Welsh	Completed	No outcome recorded
Phase 3	NCT00718471	Aug 2008 → Mar 2010	ST-elevation myocardial infarction	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00718354	Jul 2008 → Jan 2010	gastric cancer, gastroesophageal cancer	Thrombosis Research Institute	Completed	No outcome recorded
Phase 3	NCT00717938	Jun 2008 → May 2017	small cell lung carcinoma	Lund University Hospital	Completed	No outcome recorded
Phase 3	NCT00771563	Jun 2008 → Oct 2012	non-small cell lung carcinoma	University Hospital, Antwerp	Completed	No outcome recorded
Phase 3	NCT00673426	Jan → Mar 2008	kidney disorder	Azidus Brasil	Completed	No outcome recorded
Phase 3	NCT00740545	Apr 2007 → Sep 2013	—	University Hospital, Brest	Terminated	No outcome recorded
Phase 3	NCT00423319	Mar 2007 → Sep 2009	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00685958	Jul 2006 → Mar 2007	—	Sanofi	Completed	No outcome recorded
Phase 3	NCT00375076	Jun 2006 → May 2008	cancer	Medical University of Vienna	Completed	No outcome recorded
Phase 3	NCT00349180	Jun 2006 → ?	osteoarthritis, hip	Sanofi	Completed	No outcome recorded
Phase 3	NCT00328939	May 2004 → ?	venous thromboembolism	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00077792	Oct 2002 → Dec 2006	ST-elevation myocardial infarction	Sanofi	Completed	No outcome recorded
Phase 3	NCT00043784	Aug 2001 → Feb 2005	intermediate coronary syndrome, myocardial infarction, myocardial ischemia	Sanofi	Completed	No outcome recorded
Phase 3	NCT02181998	Jul 2000 → Aug 2002	myocardial infarction	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02181985	May 2000 → Apr 2001	myocardial infarction	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00182403	Sep 1998 → May 2004	pulmonary embolism, venous thromboembolism	McMaster University	Completed	No outcome recorded

Phase 449 trials
Phase 4	NCT06845423	May 2025 → May 2028 expected	venous thromboembolism	University Hospital, Brest	Recruiting	No outcome recorded
Phase 4	NCT06442267	Jul 2024 → Jan 2027 expected	hemorrhagic disease, respiratory failure, thrombotic disease	Medical University of Vienna	Recruiting	No outcome recorded
Phase 4	NCT06133803	Jan → Dec 2024	female infertility	Fertility Center of Las Vegas	Unknown	No outcome recorded
Phase 4	NCT05735639	Jan 2024 → Jun 2027 expected	varicose disease, venous thromboembolism	Imperial College London	Recruiting	No outcome recorded
Phase 4	NCT07132515	Aug 2023 → Aug 2025 overdue	cirrhosis of liver, hepatocellular carcinoma, portal vein thrombosis	Mansoura University	Recruiting	No outcome recorded
Phase 4	NCT05672550	Jun 2023 → Aug 2025	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 4	NCT06114641	Jun 2023 → Feb 2024	—	PT Bio Farma	Completed	No outcome recorded
Phase 4	NCT05255003	Aug 2022 → Dec 2026 expected	blood coagulation disease, thrombocytopenia	Tzu-Fei Wang	Recruiting	No outcome recorded
Phase 4	NCT05245877	Aug 2022 → Aug 2026 overdue	hemorrhagic disease, malignant pancreatic neoplasm, thrombotic disease	Helsinki University Central Hospital	Recruiting	No outcome recorded
Phase 4	NCT04710732	Mar 2021 → Dec 2023	venous thromboembolism	Pirogov Russian National Research Medical University	Terminated	No outcome recorded
Phase 4	NCT04731558	Feb 2021 → Feb 2027 expected	hemorrhagic disease, liver cancer, pulmonary embolism, venous thromboembolism	Helsinki University Central Hospital	Recruiting	No outcome recorded
Phase 4	NCT04406389	Oct 2020 → Apr 2021	COVID-19	Weill Medical College of Cornell University	Terminated	No outcome recorded
Phase 4	NCT04861103	Oct 2020 → Dec 2026 expected	—	University of California, Irvine	Recruiting	No outcome recorded
Phase 4	NCT04409834	Aug 2020 → Mar 2022	COVID-19, thrombotic disease, venous thromboembolism	The TIMI Study Group	Completed	No outcome recorded
Phase 4	NCT04584580	Aug → Oct 2020	COVID-19	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT04394377	Jun 2020 → Mar 2021	COVID-19	Brazilian Clinical Research Institute	Completed	No outcome recorded
Phase 4	NCT04360824	May 2020 → Apr 2021	COVID-19–associated multisystem inflammatory syndrome in adults	University of Iowa	Completed	No outcome recorded
Phase 4	NCT04520620	May → Jul 2020	COVID-19	University Hospital of Saint-Etienne	Withdrawn	No outcome recorded
Phase 4	NCT03664180	Jan 2019 → Nov 2022	ST-elevation myocardial infarction	Beijing Anzhen Hospital	Completed	No outcome recorded
Phase 4	NCT03701750	Nov 2018 → Oct 2021	infertility disorder	Shenzhen Zhongshan Urology Hospital	Unknown	No outcome recorded
Phase 4	NCT03568838	Jun 2018 → May 2020	myocardial infarction	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT04235569	Mar 2018 → Jan 2019	mitral valve disorder	Sarah Sabry Hashem	Completed	No outcome recorded
Phase 4	NCT03244020	Feb 2018 → Dec 2027 expected	bone sarcoma, hemorrhagic disease, soft tissue sarcoma, venous thromboembolism	Massachusetts General Hospital	Enrolling by invitation	No outcome recorded
Phase 4	NCT03146858	Aug → Dec 2017	strictly posterior acute myocardial infarction	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT03145675	May 2017 → Apr 2022	coronary artery disorder	Peking Union Medical College Hospital	Completed	No outcome recorded
Phase 4	NCT02444572	Oct 2015 → Jul 2020	digestive system cancer, venous thromboembolism	Les Laboratoires des Médicaments Stériles	Completed	No outcome recorded
Phase 4	NCT02658838	Apr 2015 → Aug 2016	—	Beijing Anzhen Hospital	Unknown	No outcome recorded
Phase 4	NCT03528967	Oct 2013 → Jul 2018	placental insufficiency	Les Laboratoires des Médicaments Stériles	Completed	No outcome recorded
Phase 4	NCT01916707	Jul 2013 → Jun 2017	venous thromboembolism	Intermountain Health Care, Inc.	Unknown	No outcome recorded
Phase 4	NCT01798550	Mar 2013 → Oct 2016	obesity disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT01252420	Nov 2010 → Nov 2013	pulmonary embolism, venous thromboembolism	Monash Medical Centre	Unknown	No outcome recorded
Phase 4	NCT01608347	Jan 2010 → Sep 2012	pregnancy loss, recurrent, 4	Omar Mamdouh Shaaban	Completed	No outcome recorded
Phase 4	NCT00986076	Mar 2008 → Apr 2009	—	Iladevi Cataract and IOL Research Center	Completed	No outcome recorded
Phase 4	NCT00622648	Jan 2008 → Dec 2010	—	Sanofi	Completed	No outcome recorded
Phase 4	NCT00518245	Aug 2007 → Mar 2009	intermediate coronary syndrome	Canadian Heart Research Centre	Terminated	No outcome recorded
Phase 4	NCT00585182	Jan 2007 → Apr 2008	obesity disorder, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 4	NCT00412802	Dec 2006 → Mar 2009	acute coronary syndrome, kidney failure	French Cardiology Society	Completed	No outcome recorded
Phase 4	NCT00444652	Nov 2006 → Nov 2012	venous thromboembolism	University Hospital, Strasbourg, France	Unknown	No outcome recorded
Phase 4	NCT00347490	May 2006 → Apr 2007	—	Sanofi	Completed	No outcome recorded
Phase 4	NCT00253396	Oct 2005 → Jan 2007	—	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 4	NCT00265993	Dec 2004 → Jan 2009	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 4	NCT00790387	Jun 2004 → Dec 2005	acute coronary syndrome	The Prince Charles Hospital	Completed	No outcome recorded
Phase 4	NCT00439855	Sep 2003 → Feb 2006	coronary artery disorder	Triemli Hospital	Completed	No outcome recorded
Phase 4	NCT00077805	Aug 2003 → Jul 2006	ischemic stroke	Sanofi	Completed	No outcome recorded
Phase 4	NCT00170378	Dec 2002 → Aug 2005	brain injury, venous thromboembolism	Hennepin Healthcare Research Institute	Completed	No outcome recorded
Phase 4	NCT00077818	Jun 2002 → Feb 2005	acute coronary syndrome	Sanofi	Completed	No outcome recorded
Phase 4	NCT00077753	Feb 2002 → Oct 2006	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 4	NCT00289042	Dec 1999 → Nov 2004	atrial fibrillation	The Cleveland Clinic	Completed	No outcome recorded
Phase 4	NCT00298285	? → Oct 2006	—	The Cleveland Clinic	Completed	No outcome recorded

Phase not applicable20 trials
—	NCT07658989	May 2026 → Jan 2030 expected	cardiac valvular defect, pregnancy disorder	Mount Sinai Hospital, Canada	Recruiting	No outcome recorded
—	NCT07462182	Apr → Sep 2026 expected	fetal growth restriction	Muhammad Aamir Latif	Not yet recruiting	No outcome recorded
—	NCT07506473	Apr 2026 → May 2028 expected	venous thromboembolism	University Hospital, Grenoble	Not yet recruiting	No outcome recorded
—	NCT06416566	May → Sep 2024	psoriasis	Zagazig University	Unknown	No outcome recorded
—	NCT04508439	Jun → Aug 2020	COVID-19, blood coagulation disease, pneumonia, pulmonary embolism	Hospital Regional de Alta especialidad de Ixtapaluca	Unknown	No outcome recorded
—	NCT04305756	Jun 2020 → Dec 2021	thrombotic disease, venous thromboembolism	University of Utah	Completed	No outcome recorded
—	NCT04121611	Oct 2019 → Oct 2021	basilar artery occlusion	Sunnybrook Health Sciences Centre	Unknown	No outcome recorded
—	NCT04164693	Jan 2019 → Sep 2022	thrombotic disease	First Affiliated Hospital of Chongqing Medical University	Completed	No outcome recorded
—	NCT02600260	Dec 2014 → Jul 2019	pulmonary embolism, thrombophilia, venous thromboembolism	University of Sao Paulo General Hospital	Completed	No outcome recorded
—	NCT01763606	Dec 2012 → Apr 2019	—	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
—	NCT02085824	Jul 2012 → Apr 2014	osteoarthritis, hip	Centre of Postgraduate Medical Education	Unknown	No outcome recorded
—	NCT01356615	Mar 2011	end stage renal failure	Tehran University of Medical Sciences	Completed	No outcome recorded
—	NCT01696760	Oct 2010 → Dec 2012	bone neoplasm, musculoskeletal system cancer, soft tissue sarcoma, venous thromboembolism	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
—	NCT00990236	Sep 2009 → Mar 2015	venous thromboembolism	Oregon Health and Science University	Completed	No outcome recorded
—	NCT01068795	Jul 2009 → Jan 2015	fetal growth restriction, placental abruption, preeclampsia, pregnancy disorder with abortive outcome +1	HaEmek Medical Center, Israel	Completed	No outcome recorded
—	NCT00836355	Apr → Dec 2009	ischemic stroke	NYU Langone Health	Terminated	No outcome recorded
—	NCT01086046	Jan 2009 → Jun 2012	thrombotic disease	Third Military Medical University	Unknown	No outcome recorded
—	NCT00413374	May 2006 → Apr 2008	pulmonary embolism, venous thromboembolism	Brigham and Women's Hospital	Completed	No outcome recorded
—	NCT00420667	Nov 2004 → Mar 2005	coronary artery disorder	G. d'Annunzio University	Completed	No outcome recorded
—	NCT00321009	Mar 2000 → Apr 2004	acute myocardial infarction, coronary artery disorder	Corewell Health East	Completed	No outcome recorded

Also used as a comparator or background therapy in 204 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT03100123 Comparator	Nov 2017 → Oct 2019	antiphospholipid syndrome, pregnancy disorder with abortive outcome	Ottawa Hospital Research Institute	Terminated	No outcome recorded
Phase 0	NCT00894283 Comparator	Jun 2009 → Sep 2013	pulmonary embolism, vein disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 17 trials
Phase 1	NCT07517289 Comparator	Apr → Jun 2026 overdue	—	Egyptian International Pharmaceutical Industries Co	Not yet recruiting	No outcome recorded
Phase 1	NCT06913595 Comparator	Mar 2024 → Oct 2025 overdue	venous thromboembolism	Cairo University	Active not recruiting	No outcome recorded
Phase 1	NCT03083704 Background	Feb → Sep 2017	hemorrhagic disease	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02687204 Comparator	Mar 2016 → Jun 2017	pulmonary embolism, venous thromboembolism	University of Utah	Completed	No outcome recorded
Phase 1	NCT02271113 Comparator	Oct 2014 → Mar 2016	—	GlycoMimetics Incorporated	Completed	No outcome recorded
Phase 1	NCT02070237 Comparator	Aug 2013 → Mar 2014	morbid obesity, pregnancy disorder, pulmonary embolism, thrombophlebitis +1	MemorialCare Health System	Completed	No outcome recorded
Phase 1	NCT00622115 Background	Jul → Nov 2007	thrombotic disease	Sanofi	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT04504318 Comparator	Aug 2020 → Jun 2024	venous thromboembolism	Stanford University	Completed	No outcome recorded
Phase 1/2	NCT03000673 Comparator	May → Oct 2017	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1/2	NCT02744833 Comparator	Jul → Nov 2016	venous thromboembolism	GlycoMimetics Incorporated	Terminated	No outcome recorded
Phase 1/2	NCT02923115 Background	Jun 2016 → Aug 2019	pulmonary embolism, thrombotic disease	Daiichi Sankyo	Completed	No outcome recorded
Phase 1/2	NCT02589145 Background	Jun 2016 → Apr 2019	lymphoma	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT02206100 Background	Apr → Aug 2014	—	AMAG Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1/2	NCT02128178 Comparator	Nov 2013 → Apr 2016	morbid obesity, pulmonary embolism	Mansoura University	Unknown	No outcome recorded

Phase 244 trials
Phase 2	NCT07140523 Comparator	Sep 2025 → Jun 2026 overdue	venous thromboembolism	Sirius Therapeutics Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT06963320 Comparator	Jan → Jun 2025 overdue	cardiovascular disorder	Livzon Pharmaceutical Group Inc.	Recruiting	No outcome recorded
Phase 2	NCT06454630 Comparator	Jun → Nov 2024	venous thromboembolism	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT06220123 Comparator	Feb → Dec 2024	—	Beijing Suncadia Pharmaceuticals Co., Ltd	Completed	No outcome recorded
Phase 2	NCT06293287 Comparator	Jan → Nov 2024	arterial occlusion	Zhongshan Hospital (Xiamen), Fudan University	Unknown	No outcome recorded
Phase 2	NCT06180889 Comparator	Dec 2023 → Dec 2025 overdue	osteoarthritis, knee	Suzhou Alphamab Co., Ltd.	Active not recruiting	No outcome recorded
Phase 2	NCT05618808 Comparator	May 2023 → May 2024	venous thromboembolism	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT05752461 Comparator	Apr 2023 → Apr 2024	—	Beijing Suncadia Pharmaceuticals Co., Ltd	Completed	No outcome recorded
Phase 2	NCT05498428 Background	Nov 2022 → Aug 2027 expected	non-small cell lung carcinoma	Janssen Research & Development, LLC	Recruiting	No outcome recorded
Phase 2	NCT05203705 Comparator	Mar 2022 → Mar 2023	—	Shanghai Hengrui Pharmaceutical Co., Ltd.	Terminated	No outcome recorded
Phase 2	NCT04475991 Background	Jul 2021 → Mar 2022	COVID-19	Hospital General de México Dr. Eduardo Liceaga	Terminated	No outcome recorded
Phase 2	NCT04808882 Background	Apr 2021 → Jan 2022	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT04536363 Background	Dec 2020	COVID-19	Alonso Vera Torres	Withdrawn	No outcome recorded
Phase 2	NCT04640181 Comparator	Dec 2020 → Jun 2021	COVID-19	St. David's HealthCare	Completed	No outcome recorded
Phase 2	NCT04427098 Comparator	May 2020 → Sep 2021	COVID-19	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Completed	No outcome recorded
Phase 2	NCT04374539 Comparator	Apr 2020 → Jun 2021	COVID-19	Fundacion Clinic per a la Recerca Biomédica	Terminated	No outcome recorded
Phase 2	NCT03891524 Comparator	Jun 2019 → Apr 2021	osteoarthritis, knee	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT03178864 Comparator	Mar 2019 → Oct 2022	cerebral sinovenous thrombosis	University of British Columbia	Completed	No outcome recorded
Phase 2	NCT06795698 Comparator	Mar 2019 → Dec 2024	disease of bone structure, end stage renal failure, hemorrhagic disease, venous thromboembolism	Hospital Civil de Guadalajara	Completed	No outcome recorded
Phase 2	NCT03393481 Comparator	Oct 2018 → Jan 2020	thrombotic disease	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 2	NCT03532139 Background	Jul 2018 → Dec 2023	ovarian cancer	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 2	NCT03276143 Comparator	Sep 2017 → Aug 2018	osteoarthritis, knee	Bayer	Completed	No outcome recorded
Phase 2	NCT02981472 Comparator	Jan 2017 → Oct 2021	thrombotic disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT02706249 Comparator	Apr 2016 → Dec 2020	venous thromboembolism	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT02366871 Comparator	Apr 2015 → Jun 2019	female reproductive organ cancer, venous thromboembolism	University of Colorado, Denver	Completed	No outcome recorded
Phase 2	NCT03088358 Comparator	Aug 2013 → Sep 2015	—	TeaRx LLC	Completed	No outcome recorded
Phase 2	NCT01839487 Background	May 2013 → May 2018	pancreatic ductal adenocarcinoma	Halozyme Therapeutics	Completed	No outcome recorded
Phase 2	NCT01911624 Comparator	Jan 2013 → Apr 2016	staphylococcus aureus infection	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 2	NCT03551730 Background	Dec 2012 → Sep 2015	—	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01713361 Comparator	Oct 2012 → May 2014	venous thromboembolism	Ionis Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01662908 Comparator	Aug 2012 → Jan 2014	venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 2	NCT00793234 Comparator	Dec 2008 → Jan 2010	—	ThromboGenics	Completed	No outcome recorded
Phase 2	NCT00789308 Background	Jul 2008 → Jul 2013	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT01203098 Comparator	Jul → Dec 2008	osteoarthritis, hip, thrombotic disease, venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 2	NCT00641732 Comparator	Oct 2007 → Oct 2008	venous thromboembolism	Takeda	Completed	No outcome recorded
Phase 2	NCT00408239 Comparator	Dec 2006 → Mar 2009	venous thromboembolism	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2	NCT00769873 Comparator	Oct 2006 → Apr 2009	isolated splenic vein thrombosis, portal vein thrombosis	University of Alberta	Terminated	No outcome recorded
Phase 2	NCT00396786 Comparator	Nov 2004 → Jul 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00191724 Background	Sep 2004 → Jan 2008	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00839163 Comparator	Mar 2004 → Oct 2005	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00398905 Comparator	Jan → Sep 2004	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT00074828 Comparator	Dec 2003 → May 2005	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00839826 Comparator	Dec 2002 → Nov 2003	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 2	NCT01225822 Comparator	Nov 2002 → Aug 2003	venous thromboembolism	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/39 trials
Phase 2/3	NCT06818279 Comparator	Jan 2025 → Jan 2026 overdue	cirrhosis of liver, portal vein thrombosis	Institute of Liver and Biliary Sciences, India	Not yet recruiting	No outcome recorded
Phase 2/3	NCT05293132 Background	Feb 2022 → Jun 2023	infectious disease with sepsis	Ain Shams University	Completed	No outcome recorded
Phase 2/3	NCT03570281 Comparator	Jun 2018 → May 2020	—	Samsung Medical Center	Unknown	No outcome recorded
Phase 2/3	NCT00917254 Comparator	May 2009 → Jan 2010	venous thromboembolism	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2/3	NCT00878826 Comparator	May 2009 → Aug 2011	venous thromboembolism	Stanford University	Completed	No outcome recorded
Phase 2/3	NCT00913120 Comparator	May 2009 → Mar 2010	venous thromboembolism	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2/3	NCT00902928 Comparator	Apr 2009 → Jun 2010	venous thromboembolism	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 2/3	NCT00097357 Comparator	Oct 2004 → Dec 2005	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2/3	NCT00121446 Background	Jul 2003 → ?	myocardial infarction	University of Alberta	Completed	No outcome recorded

Phase 356 trials
Phase 3	NCT07228663 Comparator	Dec 2025 → Jul 2027 expected	venous thromboembolism	McMaster University	Not yet recruiting	No outcome recorded
Phase 3	NCT07015905 Comparator	Jun 2025 → Feb 2027 expected	venous thromboembolism	Regeneron Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT06825416 Comparator	Mar 2025 → Feb 2026	—	Beijing Suncadia Pharmaceuticals Co., Ltd	Completed	No outcome recorded
Phase 3	NCT06370273 Comparator	Nov 2024 → Aug 2028 expected	thrombotic disease	Queen Mary University of London	Recruiting	No outcome recorded
Phase 3	NCT07124819 Comparator	Jul 2024 → Jan 2025	osteoarthritis, hip, osteoarthritis, knee, venous thromboembolism	Avexima Diol LLC	Completed	No outcome recorded
Phase 3	NCT05417997 Background	May → Dec 2021	COVID-19, bacterial pneumonia, influenza	RAAS Nutritionals, LLC	Completed	No outcome recorded
Phase 3	NCT05185804 Comparator	Feb → Aug 2021	COVID-19, venous thromboembolism	PharmaDiall Ltd.	Completed	No outcome recorded
Phase 3	NCT04999176 Comparator	Oct 2020 → Jul 2024	cancer, venous thromboembolism	André Luiz Malavasi Longo de Oliveira	Unknown	No outcome recorded
Phase 3	NCT04536272 Comparator	Oct 2020 → Mar 2025	heart failure, hemorrhagic disease, respiratory failure, thrombotic disease	University Medical Center Groningen	Completed	No outcome recorded
Phase 3	NCT04366960 Comparator	May 2020 → May 2021	COVID-19	Niguarda Hospital	Completed	No outcome recorded
Phase 3	NCT04462003 Comparator	Jul 2019 → Jul 2020	cancer, venous thromboembolism	Beni-Suef University	Unknown	No outcome recorded
Phase 3	NCT05172115 Comparator	Dec 2018 → Feb 2020	pulmonary embolism	Rajaie Cardiovascular Medical and Research Center	Terminated	No outcome recorded
Phase 3	NCT03395639 Comparator	May 2018 → Dec 2021	heart disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT03299296 Comparator	Jan 2017 → Jan 2018	venous thromboembolism	Ahmed AbdelMoneim Hassan Ali	Unknown	No outcome recorded
Phase 3	NCT02583191 Comparator	Mar 2016 → Jun 2019	cancer, venous thromboembolism	AIO-Studien-gGmbH	Terminated	No outcome recorded
Phase 3	NCT02774265 Comparator	Jan 2016 → May 2017	pulmonary embolism, venous thromboembolism	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 3	NCT02401594 Comparator	Dec 2015 → Apr 2018	—	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 3	NCT02379806 Comparator	Sep 2015 → Dec 2020	venous thromboembolism	University Hospital, Brest	Completed	No outcome recorded
Phase 3	NCT02072434 Comparator	Mar 2014 → Feb 2016	atrial fibrillation	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT01880216 Comparator	Jun 2013 → Jan 2015	venous thromboembolism	Berlin-Chemie Menarini	Completed	No outcome recorded
Phase 3	NCT01583218 Comparator	Mar 2012 → Dec 2015	venous thromboembolism	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01206972 Comparator	Oct 2010 → May 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01205932 Comparator	Sep 2010 → Jun 2011	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT01164046 Comparator	Aug 2010 → Jul 2014	neoplasm, venous thromboembolism	University Medical Center Groningen	Terminated	No outcome recorded
Phase 3	NCT01181167 Comparator	May 2009 → Jan 2010	venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT01181102 Comparator	Mar → Sep 2009	venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT01181141 Comparator	Oct 2008 → Aug 2009	venous thromboembolism	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00714597 Comparator	Jul 2008 → Mar 2009	venous thromboembolism	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00721760 Comparator	Jul 2008 → Oct 2009	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 3	NCT00643201 Comparator	Jul 2008 → Mar 2013	venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00718224 Comparator	Jul 2008 → May 2009	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 3	NCT00697099 Comparator	Jun 2008 → Jun 2009	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 3	NCT00680628 Comparator	May 2008 → May 2012	pulmonary embolism	Wake Forest University Health Sciences	Terminated	No outcome recorded
Phase 3	NCT00679588 Comparator	Apr 2008 → Aug 2010	venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 3	NCT00623623 Background	Mar 2008 → Sep 2012	myocardial infarction	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00657150 Comparator	Mar 2008 → Sep 2009	venous thromboembolism	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00571649 Comparator	Dec 2007 → Aug 2010	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00493896 Comparator	Jul 2007 → Apr 2010	venous thromboembolism	Eastern Virginia Medical School	Terminated	No outcome recorded
Phase 3	NCT00452530 Comparator	Jun 2007 → Jan 2009	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00457002 Comparator	Jun 2007 → May 2011	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00723216 Comparator	Mar → Dec 2007	digestive system neoplasm	Sanofi	Completed	No outcome recorded
Phase 3	NCT00440193 Comparator	Mar 2007 → Apr 2010	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00439777 Comparator	Mar 2007 → Sep 2011	pulmonary embolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00371683 Comparator	Nov 2006 → May 2008	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00362232 Comparator	Jun 2006 → Jan 2007	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00345618 Background	Jun 2006 → Oct 2010	pulmonary embolism, venous thromboembolism	Sanofi	Completed	No outcome recorded
Phase 3	NCT00332020 Comparator	Feb 2006 → May 2007	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00361894 Comparator	Feb 2006 → Jan 2007	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00329628 Comparator	Feb 2006 → Mar 2007	venous thromboembolism	Bayer	Completed	No outcome recorded
Phase 3	NCT00238667 Comparator	Nov 2005 → May 2014	carotid artery dissection, stroke disorder, vertebral artery dissection	St George's, University of London	Completed	No outcome recorded
Phase 3	NCT00111748 Comparator	Feb 2005 → Sep 2006	plasma cell myeloma	University of Arkansas	Completed	No outcome recorded
Phase 3	NCT00168818 Comparator	Nov 2004 → Jul 2006	venous thromboembolism	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00152971 Comparator	Nov 2004 → Jun 2006	venous thromboembolism	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00168805 Comparator	Nov 2004 → May 2006	osteoarthritis, knee, thrombotic disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00139815 Comparator	Apr 2003 → Dec 2005	thrombotic disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00959621 Comparator	Jan 2002 → Dec 2004	habitual spontaneous abortion	University of Helsinki	Completed	No outcome recorded

Phase 446 trials
Phase 4	NCT07243080 Comparator	Oct → Nov 2025 overdue	venous thromboembolism	Mayo Hospital Lahore	Recruiting	No outcome recorded
Phase 4	NCT07189897 Comparator	Oct 2025 → Sep 2027 expected	head and neck cancer, venous thromboembolism	Kiranya Arnold	Recruiting	No outcome recorded
Phase 4	NCT07618988 Comparator	Aug 2024 → Dec 2025	venous thromboembolism	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT06635317 Comparator	Apr → Oct 2022	venous thromboembolism	Institute for Social Security and Services for State Workers	Completed	No outcome recorded
Phase 4	NCT02856295 Comparator	Nov 2021 → Aug 2022	venous thromboembolism	HaEmek Medical Center, Israel	Completed	No outcome recorded
Phase 4	NCT03988231 Comparator	Jul 2021 → Jun 2022	pulmonary embolism, venous thromboembolism	University of Utah	Withdrawn	No outcome recorded
Phase 4	NCT04512079 Comparator	Sep 2020 → Dec 2022	COVID-19	Valentin Fuster	Completed	No outcome recorded
Phase 4	NCT04558125 Background	Sep 2020 → Jul 2021	COVID-19, pulmonary embolism	Cedars-Sinai Medical Center	Terminated	No outcome recorded
Phase 4	NCT04530578 Background	Jun → Oct 2020	COVID-19, pneumonia	Clinica San Camilo, Argentina	Unknown	No outcome recorded
Phase 4	NCT04373707 Comparator	May 2020 → Apr 2021	COVID-19, pulmonary embolism, thrombotic disease, venous thromboembolism	Central Hospital, Nancy, France	Completed	No outcome recorded
Phase 4	NCT04367831 Comparator	May 2020 → May 2021	COVID-19, thrombotic disease, venous thromboembolism	Columbia University	Completed	No outcome recorded
Phase 4	NCT04274803 Comparator	Apr 2020 → May 2021	antiphospholipid syndrome	Tanta University	Withdrawn	No outcome recorded
Phase 4	NCT04169269 Comparator	Jan → Dec 2020	venous thromboembolism	Florida Orthopaedic Institute	Unknown	No outcome recorded
Phase 4	NCT05081375 Comparator	Dec 2019 → Nov 2023	venous thromboembolism	Valleywise Health	Terminated	No outcome recorded
Phase 4	NCT03490994 Comparator	Apr 2018 → Sep 2019	heart failure	Yonsei University	Unknown	No outcome recorded
Phase 4	NCT03363035 Comparator	Jan 2018 → Nov 2021	acute coronary syndrome, intermediate coronary syndrome, myocardial infarction	Second Xiangya Hospital of Central South University	Completed	No outcome recorded
Phase 4	NCT03296033 Comparator	Oct 2017 → Jan 2022	blood coagulation disease	Wake Forest University Health Sciences	Terminated	No outcome recorded
Phase 4	NCT03081169 Comparator	Apr 2017 → Aug 2019	traumatic brain injury, venous thromboembolism	Loyola University	Withdrawn	No outcome recorded
Phase 4	NCT02865174 Comparator	Sep 2016 → Aug 2017	osteoarthritis, knee	Chang Gung Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT02474212 Comparator	May 2016 → Mar 2023	pulmonary embolism, venous thromboembolism	Tampere University Hospital	Completed	No outcome recorded
Phase 4	NCT02412982 Comparator	Mar 2016 → Jan 2019	venous thromboembolism	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT02396732 Background	Feb 2016 → May 2018	venous thromboembolism	University of Miami	Terminated	No outcome recorded
Phase 4	NCT03158792 Comparator	Oct 2015 → Jul 2017	impaired renal function disease, venous thromboembolism	Lebanese American University	Completed	No outcome recorded
Phase 4	NCT02696330 Comparator	Sep 2015 → Sep 2016	female infertility	Ain Shams Maternity Hospital	Unknown	No outcome recorded
Phase 4	NCT02861105 Comparator	Jan 2015 → Jan 2016	infertility disorder	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT02326051 Comparator	Dec 2014 → Feb 2017	antiphospholipid syndrome, pregnancy loss, recurrent, 4	Mohamed Sayed Abdelhafez	Completed	No outcome recorded
Phase 4	NCT02303171 Comparator	Nov 2014 → Dec 2024	antiphospholipid syndrome, pregnancy loss, recurrent, 4	Mohamed Sayed Abdelhafez	Unknown	No outcome recorded
Phase 4	NCT03805672 Comparator	Sep 2014 → Jul 2015	thrombotic disease, venous thromboembolism	Oregon Health and Science University	Terminated	No outcome recorded
Phase 4	NCT02389582 Comparator	May 2014 → Nov 2015	coronary artery disorder	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 4	NCT02095509 Comparator	Mar 2014 → Jun 2016	venous thromboembolism	Tampere University Hospital	Completed	No outcome recorded
Phase 4	NCT02342444 Comparator	Feb 2014 → Dec 2024	traumatic brain injury, venous thromboembolism	Oregon Health and Science University	Unknown	No outcome recorded
Phase 4	NCT01970202 Comparator	Nov 2013 → Dec 2015	obesity disorder	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 4	NCT01970280 Comparator	Sep 2013 → Nov 2014	—	Dr. Sidney Ben Chetrit	Unknown	No outcome recorded
Phase 4	NCT01828697 Comparator	Apr 2013 → Oct 2021	pulmonary embolism, venous thromboembolism	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 4	NCT01729559 Comparator	Nov 2012 → Sep 2014	pulmonary embolism, venous thromboembolism	Scripps Health	Completed	No outcome recorded
Phase 4	NCT01747746 Background	Oct 2012 → Oct 2014	atrial fibrillation, hemorrhagic disease, stroke disorder, venous thromboembolism	Cook County Health	Completed	No outcome recorded
Phase 4	NCT01687491 Comparator	Jul 2012 → May 2013	acute coronary syndrome	Les Laboratoires des Médicaments Stériles	Completed	No outcome recorded
Phase 4	NCT02379663 Comparator	Jan 2012 → Jan 2013	avascular necrosis, osteoarthritis, hip	Samsung Medical Center	Completed	No outcome recorded
Phase 4	NCT01354704 Comparator	Mar 2011 → Jul 2015	venous thromboembolism	Les Laboratoires des Médicaments Stériles	Completed	No outcome recorded
Phase 4	NCT01956955 Comparator	Jan 2011 → Dec 2013	—	Ataturk University	Unknown	No outcome recorded
Phase 4	NCT01063426 Comparator	Nov 2009 → Dec 2011	venous thromboembolism	Hallym University Medical Center	Unknown	No outcome recorded
Phase 4	NCT01021488 Comparator	Oct 2009 → Dec 2011	thrombotic disease, vein disorder, venous thromboembolism	Hallym University Medical Center	Unknown	No outcome recorded
Phase 4	NCT00699465 Comparator	Aug 2008 → Jul 2013	intracerebral hemorrhage	University of Oulu	Unknown	No outcome recorded
Phase 4	NCT00669149 Comparator	Jun 2008 → Aug 2013	coronary artery disorder	Centre Hospitalier de PAU	Terminated	No outcome recorded
Phase 4	NCT00351663 Comparator	Feb 2007 → Apr 2014	venous thromboembolism	Shaare Zedek Medical Center	Completed	No outcome recorded
Phase 4	NCT00232271 Comparator	Aug 2005 → Jan 2011	venous thromboembolism	Melbourne Health	Terminated	No outcome recorded

Phase not applicable32 trials
—	NCT07329946 Background	Sep 2026 → Feb 2027 expected	chronic obstructive pulmonary disease	Pierachille Santus, MD, PhD	Not yet recruiting	No outcome recorded
—	NCT07710482 Comparator	Aug 2026 → Jul 2027 expected	—	Menoufia University	Not yet recruiting	No outcome recorded
—	NCT07559643 Comparator	Aug 2026 overdue	obesity disorder, venous thromboembolism	University College Dublin	Not yet recruiting	No outcome recorded
—	NCT07116239 Comparator	Sep 2025 → Feb 2026 overdue	nephrotic syndrome	Peking University People's Hospital	Not yet recruiting	No outcome recorded
—	NCT07270263 Comparator	Nov 2024 → Apr 2026 overdue	leukemia, lymphoma, pulmonary embolism, venous thromboembolism	Medical University of Gdansk	Recruiting	No outcome recorded
—	NCT06689241 Comparator	Oct 2024 → Dec 2025 overdue	morbid obesity	Alexandria University	Recruiting	No outcome recorded
—	NCT06049758 Comparator	Jan 2024 → Jan 2026 overdue	lymph node disorder	General Committee of Teaching Hospitals and Institutes, Egypt	Not yet recruiting	No outcome recorded
—	NCT05484557 Comparator	Sep 2023 → Aug 2025 overdue	spinal cord injury	Loewenstein Hospital	Recruiting	No outcome recorded
—	NCT05334654 Comparator	Apr → Jun 2022	COVID-19, acute respiratory failure	University Magna Graecia	Completed	No outcome recorded
—	NCT05901337 Background	Mar → Jun 2022	—	Cairo University	Completed	No outcome recorded
—	NCT05977166 Comparator	Mar → Jun 2022	long COVID-19	Cairo University	Completed	No outcome recorded
—	NCT05058924 Comparator	Aug 2021 → Feb 2024	venous thromboembolism	Mount Sinai Hospital, Canada	Completed	No outcome recorded
—	NCT05311813 Comparator	Jun → Dec 2021	COVID-19	Beni-Suef University	Completed	No outcome recorded
—	NCT05237726 Comparator	Apr 2020 → Feb 2022	—	King Abdullah International Medical Research Center	Completed	No outcome recorded
—	NCT03671174 Background	Aug 2019 → Sep 2021	habitual spontaneous abortion, undifferentiated connective tissue syndrome	RenJi Hospital	Unknown	No outcome recorded
—	NCT03277001 Comparator	Oct 2017 → Jul 2019	chronic obstructive pulmonary disease, venous thromboembolism	Huashan Hospital	Unknown	No outcome recorded
—	NCT03044574 Background	Feb 2017 → Sep 2018	venous thromboembolism	Pirogov Russian National Research Medical University	Completed	No outcome recorded
—	NCT03465735 Background	Jan 2017 → Aug 2019	venous thromboembolism	Mayo Clinic	Terminated	No outcome recorded
—	NCT02744092 Comparator	Dec 2016 → Oct 2020	cancer, pulmonary embolism, thrombotic disease, venous thromboembolism	Alliance Foundation Trials, LLC.	Completed	No outcome recorded
—	NCT02375646 Comparator	May 2015 → May 2017	—	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT02411331 Background	Mar 2015 → Jan 2017	staphylococcal infection	University Hospital, Clermont-Ferrand	Unknown	No outcome recorded
—	NCT02260908 Comparator	Oct 2014 → Sep 2016	intracerebral hemorrhage	McMaster University	Unknown	No outcome recorded
—	NCT01999179 Background	Jun 2014 → Apr 2019	neoplasm, venous thromboembolism	Medical College of Wisconsin	Completed	No outcome recorded
—	NCT01965002 Background	May 2014 → Mar 2015	soft tissue neoplasm	Pejman Ghanouni	Terminated	No outcome recorded
—	NCT02795065 Comparator	Mar 2014 → Mar 2016	venous thromboembolism	Mohamed Sayed Mohamed Abbas	Completed	No outcome recorded
—	NCT01631877 Background	Jun 2012 → Jun 2017	portal vein thrombosis	Institute of Liver and Biliary Sciences, India	Withdrawn	No outcome recorded
—	NCT01588171 Comparator	May 2012 → Oct 2013	venous thromboembolism	Hawler Medical University	Completed	No outcome recorded
—	NCT01325779 Comparator	Mar 2011 → Feb 2013	venous thromboembolism	Lisa Louwers	Withdrawn	No outcome recorded
—	NCT01589393 Comparator	Sep 2010 → Dec 2013	intracerebral hemorrhage	McMaster University	Completed	No outcome recorded
—	NCT02240927 Comparator	Jan 2010 → Jun 2015	cardiac valvular defect, pregnancy disorder	Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital	Unknown	No outcome recorded
—	NCT00521885 Comparator	Sep 2007 → Sep 2009	venous thromboembolism	Lehigh Valley Hospital	Terminated	No outcome recorded
—	NCT00358735 Comparator	Jun 2006 → Sep 2008	hemorrhagic disease, pulmonary embolism, venous thromboembolism	Medical Compression Systems	Completed	No outcome recorded

Phase not stated1 trial
—	NCT01049633 Background	—	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	No longer available	No outcome recorded

Press releases naming this drug 6 releases

Date	Issuer	Release
2015-02-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Bolsters Injectable Portfolio with Launch of Generic Lovenox® and Generic Zyvox® in the United States tevapharm.com ↗
2011-12-13	Daiichi Sankyo	Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery daiichisankyo.com ↗
2011-01-25	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives FDA Action Letter For Generic Lovenox® tevapharm.com ↗
2010-12-08	Daiichi Sankyo	EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL HIP REPLACEMENT daiichisankyo.com ↗
2010-07-23	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Comments on Generic Lovenox® Approval tevapharm.com ↗
2010-07-12	Daiichi Sankyo	EDOXABAN DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH ENOXAPARIN SODIUM IN PREVENTING VTE AFTER TOTAL KNEE REPLACEMENT daiichisankyo.com ↗

Evidence & citations 32 cited values

Every value below carries the sentence it was read from. 385 sources stand behind the page.

Field	Value	Cited text
Known as	enoxaparin sodium	“SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin...” NCT00289042 ↗ 40 “In this multicenter, randomized, open-label, active-comparator, phase 3 trial, 92 patients were randomized 2:1 to receive edoxaban 30mg once daily (n=62) or enoxaparin sodium...” PMID 24680549 ↗ Mar 2014 “Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or...” NCT01588171 ↗ “A Multinational, Multicentre, Randomized, Open, Parallel Group Study on the Efficacy and Safety of Bemiparin Sodium (LMWH) Compared to Enoxaparin Sodium (LMWH) in the Treatment...” NCT01880216 ↗ “Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local...” NCT00679588 ↗ “For patients weighing less than 80kg, enoxaparin sodium 4000IU was administered once daily, while for those weighing over 80kg, enoxaparin sodium 4000IU was administered every 12 hours.” NCT04164693 ↗ “Multicenter, Non-comparative, Open-label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery” NCT00685958 ↗ “Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs” NCT00232271 ↗ “The Enoxaparin sodium is one that acts as antithrombin-factor Xa inhibitor of acting directly on the inactivation of antithrombin.” NCT00673426 ↗ “Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day” NCT01590173 ↗ “Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation” NCT06049758 ↗ “Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days” NCT00714597 ↗ “Evaluate the efficacy and safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days” NCT00723216 ↗ “Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days” NCT00331838 ↗ “Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily” NCT06293287 ↗ “Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets” NCT06220123 ↗ “Drug: Enoxaparin Sodium 100 MG/ML Prefilled Syringe” NCT04235569 ↗ “Enoxaparin sodium 20 mg, once daily subcutaneously” NCT01608347 ↗ “low molecular weight heparin (enoxaparin sodium)” NCT07270263 ↗ “Enoxaparin Sodium (Lovenox®)” NCT02744833 ↗ “Enoxaparin sodium injection” NCT05752461 ↗ “Enoxaparin sodium (XRP4563)” NCT00077792 ↗ “Drug: Enoxaparin Sodium” NCT05334654 ↗ “Enoxaparin Sodium” NCT04990830 ↗ NCT00916669 ↗ NCT05484557 ↗ NCT00077805 ↗ NCT06963320 ↗ NCT00077818 ↗ NCT04406389 ↗ NCT03083704 ↗ NCT00349180 ↗ NCT00789308 ↗ NCT01181102 ↗ NCT01181167 ↗ NCT01203098 ↗ NCT02081950 ↗ NCT00697099 ↗ NCT03701750 ↗ NCT02232802 ↗ NCT06153394 ↗
Known as	clexan	“HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)” NCT07132515 ↗
Known as	Clexane	“Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg...” NCT01970280 ↗ 16 “The hypothesis of this trial is that the test drug (Enoxalow® - T) pharmacodynamics parameters are similar to the comparator drug (Clexane® - C) in healthy subjects following...” NCT01692171 ↗ “Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs” NCT00232271 ↗ “LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.” NCT03044574 ↗ “Low molecular weigh heparins such as enoxaparin (clexane) have more favorable pharmacokinetic/ pharmacodynamic profiles, equivalent or improved efficacy” NCT00351663 ↗ “Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.” NCT04400799 ↗ “enoxaparin (100 mg/mL) 100-mg SC injection manufactured by Rovi Spain, or Clexane (100 mg/mL) 100-mg SC injection manufactured by Sanofi EU” NCT03363477 ↗ “Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day” NCT01590173 ↗ “Reference: Clexane (Enoxaparin Sodium 40mg/0.4ml) manufactured by Sanofi Aventis, Egypt.” NCT07517289 ↗ “Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily” NCT04274803 ↗ “Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis” NCT01692158 ↗ “reference enoxaparin (Clexane®, Sanofi-Aventis)” NCT01356992 ↗ “Clexane (enoxaparine) 40 mg sc” NCT00959621 ↗ “Clexane (enoxaparin)” NCT00874484 ↗ “Clexane 40-60 mg/d” NCT04374539 ↗ NCT05185804 ↗ NCT02856295 ↗
Known as	Enaoxaprin sodium	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02325479 ↗
Known as	ENOXAMED	“patients are given a curative dose of Enoxaparin (ENOXAMED)” NCT02152423 ↗
Known as	enoxaparin	“This prospective randomized trial will compare outcomes in patients receiving aspirin (81mg daily) in combination with a low-molecular weight heparin (LMWH) (enoxaparin...” NCT06133803 ↗ 336 “The initial dose will be a twice daily therapeutic dose of 1.35U/kg (pregnancy weight) of enoxaparin or 135 U/kg (pregnancy weight) of dalteparin using prefilled syringes...” NCT07658989 ↗ “PURPOSE: To determine if intraocular infusion of low-molecular-weight heparin (enoxaparin) reduces postoperative inflammation in pediatric eyes undergoing cataract surgery with...” PMID 22541652 ↗ Apr 2012 “Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if...” NCT04360824 ↗ “For patients weighing less than 80kg, enoxaparin sodium 4000IU was administered once daily, while for those weighing over 80kg, enoxaparin sodium 4000IU was administered every 12 hours.” NCT04164693 ↗ “Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.” NCT05848713 ↗ “Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.” NCT04976465 ↗ “40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation” NCT02861105 ↗ “Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs” NCT00232271 ↗ “LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.” NCT03044574 ↗ “dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated” NCT03490994 ↗ “Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin.” NCT02375646 ↗ “Low-molecular-weight heparin (dalteparin or enoxaparin) was administered subcutaneously at a dose of 100 IU/kg every 12 hours (n = 352).” PMID 16926353 ↗ Aug 2006 “Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous” NCT03671174 ↗ “Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.” PMID 25636341 ↗ Jan 2015 “with enoxaparin sodium (enoxaparin) for thromboprophylaxis after total knee arthroplasty (TKA) in patients in Japan and Taiwan.” PMID 25294589 ↗ Sep 2014 “Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose.” NCT06662253 ↗ “Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal” NCT01999179 ↗ “Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.” NCT05058924 ↗ “doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours” NCT05977166 ↗ “The pharmacokinetics of enoxaparin administered subcutaneously in the intensive care unit patient are not described.” NCT04520620 ↗ “Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day” NCT01590173 ↗ “If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.” NCT04808882 ↗ “patients were assigned to either an intermittent pneumatic compression (IPC) only or an IPC plus enoxaparin.” PMID 25012265 ↗ Jul 2014 “Enoxaparin, a low molecular weight heparin (LMWH), is effective in prevention and treatment of VTE.” PMID 24641937 ↗ Mar 2014 “Comparison of Anti-Xa Activity in the Treatment With Enoxaparin in ACS Admitted to the Emergency.” NCT01687491 ↗ “patients received edoxaban 30 mg or enoxaparin 2000 IU (20 mg) twice daily for 11 to 14 days.” PMID 27980462 ↗ Dec 2016 “low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours” NCT05901337 ↗ “Group 1 : Enoxaparin 40 mg+ placebo, Group 2: Enoxaparin 40 +ASA 100 mg, Group 3: ASA.” NCT00959621 ↗ “Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours” NCT04536363 ↗ “prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours)” NCT05293132 ↗ “Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present” NCT04475991 ↗ “Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily.” NCT01608347 ↗ “or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg” NCT04121611 ↗ “Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily” NCT03200613 ↗ “Enoxaparin: 40 mg subcutaneously OD (or 30 mg subcutaneously BID)” NCT07228663 ↗ “Subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours.” NCT04600141 ↗ “Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin)” NCT03178864 ↗ “LMWH options include: Tinzaparin, Enoxaparin, or Dalteparin.” NCT04444700 ↗ “A syringe of enoxaparin active substance 4000 UI once daily” NCT02401594 ↗ “LMWH options include: Tinzaparin, Enoxaparin or Dalteparin.” NCT04362085 ↗ “Participants will receive 40 mg enoxaparin twice daily” NCT03212365 ↗ “Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.” NCT01583218 ↗ “Preferred therapeutic anticoagulant is enoxaparin.” NCT04372589 ↗ “Enoxaparin 1 mg/kg subcutaneously every 12 hours” NCT04485429 ↗ “Dalteparin, Enoxaparin, Nadroparin, Tinzaparin” NCT06494878 ↗ “Low Molecular Weight Heparin (LMWH)-Enoxaparin” NCT02984384 ↗ “Enoxaparin 1 mg/kg subcutaneous every 12 hours” NCT04584580 ↗ “Enoxaparin has been the most studied.” NCT02152423 ↗ “Enoxaparin 1 mg/kg BW twice daily” NCT02583191 ↗ “enoxaparin 4000-6000IU o.d.” NCT07140211 ↗ “Full amount enoxaparin” NCT02658838 ↗ “Enoxaparin (Clexane®)” NCT01817257 ↗ “Enoxaparin (Lovenox)” NCT03465735 ↗ “Drug: Enoxaparin” NCT04558125 ↗ “enoxaparin” NCT01164046 ↗ “Enoxaparin” NCT02981472 ↗ “Enoxaparin” NCT03100123 ↗ “Enoxaparin” NCT01086046 ↗ “Enoxaparin” NCT02798471 ↗ “Enoxaparin” NCT03395639 ↗ NCT04401293 ↗ NCT00412802 ↗ NCT05255003 ↗ NCT04999176 ↗ NCT00990236 ↗ NCT00074828 ↗ NCT03003390 ↗ NCT01828697 ↗ NCT00657150 ↗ NCT00289042 ↗ NCT03081169 ↗ NCT00077753 ↗ NCT05752461 ↗ NCT02744833 ↗ NCT02072434 ↗ NCT02744092 ↗ NCT06220123 ↗ NCT00077792 ↗ NCT00894283 ↗ NCT02389582 ↗ NCT04354155 ↗ NCT06118957 ↗ NCT03000673 ↗ NCT04558892 ↗ NCT02206100 ↗ NCT00077844 ↗ NCT03244020 ↗ NCT06114641 ↗ NCT00361894 ↗ NCT01707732 ↗ NCT04483960 ↗ NCT02326051 ↗ NCT04924322 ↗ NCT05895136 ↗ NCT01068795 ↗ NCT00362232 ↗ NCT00191724 ↗ NCT04409834 ↗ NCT03083184 ↗ NCT05081375 ↗ NCT00139815 ↗ NCT03145675 ↗ NCT04646655 ↗ NCT05735639 ↗ NCT00913120 ↗ NCT00351663 ↗ NCT03891524 ↗ NCT01388322 ↗ NCT06517563 ↗ NCT00836355 ↗ NCT03146858 ↗ NCT02444572 ↗ NCT00643201 ↗ NCT03363477 ↗ NCT00423319 ↗ NCT05237726 ↗ NCT01325779 ↗ NCT01911624 ↗ NCT01713361 ↗ NCT04408235 ↗ NCT00673426 ↗ NCT07506473 ↗ NCT00170378 ↗ NCT06818279 ↗ NCT07312851 ↗ NCT04731558 ↗ NCT00358735 ↗ NCT02486666 ↗ NCT01063426 ↗ NCT00623623 ↗ NCT00265993 ↗ NCT06825416 ↗ NCT03988231 ↗ NCT02474212 ↗ NCT00097357 ↗ NCT02095509 ↗ NCT06795698 ↗ NCT03363035 ↗ NCT00874484 ↗ NCT05618808 ↗ NCT00398905 ↗ NCT02865174 ↗ NCT00306254 ↗ NCT00771563 ↗ NCT01696760 ↗ NCT00839826 ↗ NCT00518245 ↗ NCT01181141 ↗ NCT04373707 ↗ NCT05172115 ↗ NCT02379806 ↗ NCT02379663 ↗ NCT00680628 ↗ NCT02159287 ↗ NCT01662908 ↗ NCT01747746 ↗ NCT01970202 ↗ NCT04427098 ↗ NCT02672566 ↗ NCT00413374 ↗ NCT04305756 ↗ NCT00585182 ↗ NCT04462003 ↗ NCT02271113 ↗ NCT04762992 ↗ NCT00321009 ↗ NCT04402762 ↗ NCT06180889 ↗ NCT07710482 ↗ NCT05417997 ↗ NCT07132515 ↗ NCT01206972 ↗ NCT06416566 ↗ NCT00641732 ↗ NCT03339349 ↗ NCT00493896 ↗ NCT00298285 ↗ NCT01354704 ↗ NCT04235569 ↗ NCT01058759 ↗ NCT01970280 ↗ NCT03158792 ↗ NCT02181998 ↗ NCT02774265 ↗ NCT00723216 ↗ NCT02589145 ↗ NCT04492254 ↗ NCT07499037 ↗ NCT01839487 ↗ NCT04640181 ↗ NCT00622648 ↗ NCT01916707 ↗ NCT00785421 ↗ NCT07189897 ↗ NCT00152971 ↗ NCT02070237 ↗ NCT01631877 ↗ NCT07270263 ↗ NCT04400799 ↗ NCT01051778 ↗ NCT04345848 ↗ NCT04530578 ↗ NCT00669149 ↗ NCT07116239 ↗ NCT00769873 ↗ NCT01880216 ↗ NCT01573169 ↗ NCT00718471 ↗ NCT00345618 ↗ NCT02342444 ↗ NCT07015905 ↗ NCT00908960 ↗ NCT00633061 ↗ NCT02600260 ↗ NCT00986765 ↗ NCT00718354 ↗ NCT02411292 ↗ NCT03299296 ↗ NCT06635317 ↗ NCT00420667 ↗ NCT04377997 ↗ NCT00331838 ↗ NCT02706249 ↗ NCT00440193 ↗ NCT03254511 ↗ NCT00902928 ↗ NCT04367831 ↗ NCT03551730 ↗ NCT00439855 ↗ NCT00439777 ↗ NCT00685958 ↗ NCT01474902 ↗ NCT06689241 ↗ NCT02704052 ↗ NCT02128178 ↗ NCT00375076 ↗ NCT07462182 ↗ NCT00622115 ↗ NCT00917254 ↗ NCT00714597 ↗ NCT01798550 ↗ NCT01014403 ↗ NCT00238667 ↗ NCT01965002 ↗ NCT00679588 ↗ NCT04486508 ↗ NCT00790387 ↗ NCT03805672 ↗ NCT00121446 ↗ NCT04528888 ↗ NCT00375609 ↗ NCT00396786 ↗ NCT02412982 ↗ NCT01763606 ↗ NCT05245877 ↗ NCT01049633 ↗ NCT01356329 ↗ NCT00457002 ↗ NCT04710732 ↗ NCT02696330 ↗ NCT00253396 ↗ NCT04394377 ↗ NCT03528967 ↗ NCT07243080 ↗ NCT00426127 ↗ NCT06049758 ↗ NCT00444652 ↗ NCT00721760 ↗ NCT00043784 ↗ NCT00699465 ↗ NCT04504318 ↗ NCT03664180 ↗ NCT00718224 ↗ NCT02085824 ↗ NCT05311813 ↗ NCT00878826 ↗ NCT02396732 ↗ NCT07517289 ↗ NCT01205932 ↗ NCT03570281 ↗ NCT03532139 ↗ NCT01356615 ↗ NCT03296033 ↗ NCT03812328 ↗ NCT02171559 ↗ NCT02181985 ↗ NCT00571649 ↗ NCT00408239 ↗ NCT00717938 ↗ NCT06531525 ↗ NCT01252420 ↗ NCT07559643 ↗ NCT00793234 ↗ NCT00329628 ↗ NCT02260908 ↗ NCT00332020 ↗ NCT06442267 ↗ NCT02795065 ↗ NCT01356992 ↗ NCT03276143 ↗ NCT02366871 ↗ NCT03568838 ↗ NCT00839163 ↗ NCT02687204 ↗ NCT03088358 ↗ NCT04169269 ↗ NCT07618988 ↗ NCT01021488 ↗ NCT03277001 ↗ NCT06628778 ↗ NCT07140523 ↗ NCT01729559 ↗ NCT03251963 ↗ NCT06293287 ↗ NCT01149304 ↗ NCT06454630 ↗ NCT00452530 ↗ NCT04508439 ↗ NCT02923115 ↗ NCT05334654 ↗ NCT02303171 ↗ NCT01956955 ↗ NCT03393481 ↗ NCT05878899 ↗ NCT01588171 ↗ NCT05672550 ↗ NCT04512079 ↗ NCT01225822 ↗ NCT00882635 ↗ NCT00371683 ↗ NCT00168805 ↗ NCT00168818 ↗ NCT01589393 ↗ NCT06370273 ↗ NCT05203705 ↗ NCT04366960 ↗
Known as	Enoxaparin (Clexane)	“Enoxaparin (Clexane®)” NCT01817257 ↗
Known as	Enoxaparin (Lovenox)	“Enoxaparin (Lovenox)” NCT03465735 ↗
Known as	Enoxaparin sodium (preservative free)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Enoxaparin sodium salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Enoxaparina de sodio	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	enoxaparine	“Clexane (enoxaparine) 40 mg sc” NCT00959621 ↗ 11 “Enoxaparine 4000 UI” NCT06845423 ↗ “Enoxaparine” NCT04536272 ↗ “Enoxaparine” NCT06913595 ↗ NCT01945879 ↗ NCT00740545 ↗ NCT00347490 ↗ NCT02271295 ↗ NCT02411331 ↗ NCT00402467 ↗ NCT02240927 ↗ NCT00328939 ↗
Known as	Enoxaparine sodique	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Inhixa	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Klexane	“Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)” NCT02474212 ↗ 1 “Klexane® (Enoxaparinsodium)” NCT00789308 ↗
Known as	Lovenox	“This prospective randomized trial will compare outcomes in patients receiving aspirin (81mg daily) in combination with a low-molecular weight heparin (LMWH) (enoxaparin...” NCT06133803 ↗ 17 “SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin...” NCT00289042 ↗ “A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily...” NCT00894283 ↗ “All participants will receive one dose of pre-operative low molecular weight heparin (Lovenox®) subcutaneously, 2 hours prior to surgery.” NCT00769873 ↗ “Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin.” NCT00633061 ↗ “Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14” NCT00111748 ↗ “low dose or high dose enoxaparin (Lovenox), a blood thinner.” NCT03805672 ↗ “patients are given a curative dose of Enoxaparin (LOVENOX)” NCT02152423 ↗ “Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin))” NCT00986765 ↗ “enoxaparin (Lovenox) at the judgment of their physician.” NCT02070237 ↗ “Originator Enoxaparin with a trade name is Lovenox.” NCT06114641 ↗ “Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.” NCT01474902 ↗ “Enoxaparin Prefilled Syringe [Lovenox]” NCT04354155 ↗ “Enoxaparin Prefilled Syringe [Lovenox]” NCT04402762 ↗ “Enoxaparin Sodium (Lovenox®)” NCT02744833 ↗ NCT06004674 ↗ NCT04861103 ↗ NCT00521885 ↗
Known as	Lovenox (preservative free)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	LovenoxTM	“Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)” NCT01356329 ↗
Known as	Low Molecular Weight Heparin (LMWH)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05498428 ↗
Known as	PK 10169	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	RP54563	“Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement” NCT00349180 ↗ 2 “Multicenter, Non-comparative, Open-label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery” NCT00685958 ↗ “Evaluate the efficacy and safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days” NCT00723216 ↗
Known as	Sodium enoxaparin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07124819 ↗ 1 NCT01308528 ↗
Known as	Standard of Care (SOC)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07329946 ↗
Known as	Thorinane	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201476 ↗
Known as	Tinzaparine	“Tinzaparine 3500 UI” NCT06845423 ↗ 1 “Tinzaparine” NCT04536272 ↗
Known as	Versa	“Versa® (enoxaparin - Eurofarma)” NCT01356992 ↗
Known as	XRP4563	“Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)” NCT00349180 ↗ 2 “Enoxaparin sodium (XRP4563)” NCT00077792 ↗ “enoxaparin (XRP4563)” NCT00685958 ↗
Action	Activate	“Antithrombin-III activator” CHEMBL1201476 ↗
Action	Inhibit	“enoxaparin predominantly target factor Xa but to some extent also inhibit thrombin” PMID 19657123 ↗ Aug 2009
Modality	Other / unclassified	“low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis)” NCT00289042 ↗
Route	Subcutaneous	“Subcutaneous enoxaparin (n = 4993)” PMID 15238590 ↗ Jul 2004
Target	SERPINC1	“Antithrombin-III activator” CHEMBL1201476 ↗